Medication Interactions with Apixaban

Introduction to Apixaban Interactions

• The British Society of Gastroenterology recommends avoiding all NSAIDs (ibuprofen, naproxen, etc.) as they significantly increase bleeding risk when combined with apixaban 1
• The British Society of Gastroenterology suggests using acetaminophen (Tylenol) instead for pain management, as it does not increase bleeding risk when combined with apixaban 1

Antiplatelet and Anticoagulant Interactions

• The European Heart Journal advises avoiding prasugrel and ticagrelor unless specifically directed by your cardiologist when taking apixaban 2
• The European Heart Journal recommends avoiding combination of apixaban with SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin-norepinephrine reuptake inhibitors) when possible, or monitoring closely for bleeding signs 2

Antibiotic Interactions

• Rifampin dramatically reduces apixaban levels, increasing clot risk, according to Praxis Medical Insights 3
• Nafcillin reduces apixaban effectiveness over time, as reported by Praxis Medical Insights 3
• Erythromycin (moderate CYP3A4 inhibitor) requires closer bleeding monitoring when combined with apixaban, according to Praxis Medical Insights 3
• Trimethoprim-sulfamethoxazole may affect kidney function, compounding risk when combined with apixaban, as noted by Praxis Medical Insights 3

Antidepressant and Psychiatric Medication Interactions

• The European Heart Journal recommends avoiding combination of apixaban with SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin-norepinephrine reuptake inhibitors) when possible, or monitoring closely for bleeding signs 2

Herbal Supplement and Natural Product Interactions

• Berberine inhibits CYP3A4 and increases apixaban levels, raising bleeding risk, according to Praxis Medical Insights 4
• Consider switching to edoxaban (minimally metabolized by CYP3A4) if berberine is necessary, as suggested by Praxis Medical Insights 4

High-Risk Patient Populations

• Elderly patients (>75 years), those with kidney impairment (CrCl 30-50 mL/min), and patients weighing <50 kg face compounded bleeding risk with any interacting medication, according to Praxis Medical Insights 3
• Even moderate CYP3A4/P-gp inhibitors can cause clinically significant bleeding in these populations, as reported by Circulation: Arrhythmia and Electrophysiology and Praxis Medical Insights 5, 3

Cancer Therapy Interactions

• Alectinib, brigatinib, capmatinib, ceritinib, entrectinib, lorlatinib are contraindicated or require significant dose adjustments when combined with apixaban, according to the European Respiratory Review 6, 7, 8
• Erlotinib and gefitinib can be used safely with apixaban, as reported by the European Respiratory Review 7, 8
• Edoxaban represents the safest DOAC option with most cancer therapies due to minimal CYP3A4 metabolism, according to the European Respiratory Review and Praxis Medical Insights 6, 7, 8, 3, 4

Monitoring and Management Strategies

• Monitor for bleeding signs including unusual bruising, blood in urine/stool, prolonged bleeding from cuts, or unexplained bleeding throughout therapy with any potentially interacting medication, as recommended by Praxis Medical Insights 1, 3
• Assess kidney function before initiating any interacting medication and monitor for deterioration, according to Praxis Medical Insights 3, 4
• Consider PPI prophylaxis to reduce gastrointestinal bleeding risk when combining with NSAIDs or antiplatelet agents, though this does not eliminate systemic bleeding risk, as suggested by the European Heart Journal and Praxis Medical Insights 2, 1

Sertraline and Apixaban Interaction: Pharmacokinetic Profile and Clinical Management

Metabolic Pathways

Pharmacokinetic Interaction

Dose‑Adjustment Recommendations

Bleeding Risk in Patients Receiving Antiplatelet Therapy

Considerations for Strong CYP3A4 Inhibitors

Co‑administration of Fioricet with Apixaban and Levetiracetam

Pharmacokinetic Compatibility

• Butalbital does not induce CYP3A4 or modulate P‑gp, so it does not alter apixaban plasma concentrations via pharmacokinetic mechanisms (expert consensus, Mayo Clinic Proceedings 2021) 12
• No pharmacokinetic interaction exists between butalbital and levetiracetam because levetiracetam is not metabolized by cytochrome P450 enzymes and butalbital’s GABA‑receptor activity does not affect levetiracetam clearance (pharmacology review, Annals of Emergency Medicine 2014) 13

Bleeding Risk and Monitoring

• Fioricet can be used together with apixaban and levetiracetam, but careful monitoring for bleeding is required and the combination should be avoided on the day of any surgical procedure (clinical guideline, Mayo Clinic Proceedings 2021) 12

Peri‑operative Management

• Hold Fioricet on the day of any surgical procedure according to consensus guidelines for butalbital management (expert consensus, Mayo Clinic Proceedings 2021) 12
• For patients on long‑term Fioricet, taper slowly over ~2 weeks before surgery; if tapering is not feasible, continue the medication pre‑operatively to prevent withdrawal seizures (clinical recommendation, Mayo Clinic Proceedings 2021) 12
• Continue apixaban and levetiracetam peri‑operatively unless specific surgical contraindications exist (expert consensus, Mayo Clinic Proceedings 2021) 12

Dependence, Withdrawal, and Safe‑Use Considerations

• Long‑term use of butalbital can lead to dependence; abrupt discontinuation may precipitate intractable seizures and withdrawal symptoms (clinical warning, Mayo Clinic Proceedings 2021) 12
• Avoid prescribing Fioricet for extended periods because of its addiction potential; safer alternatives such as acetaminophen alone are preferred (clinical recommendation, Mayo Clinic Proceedings 2021) 12
• Do not assume all headache medications are safe with apixaban—agents like triptans and ergotamine have distinct interaction profiles and peri‑operative recommendations (clinical caution, Mayo Clinic Proceedings 2021) 12